{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:08:51Z","timestamp":1782860931626,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12152-8","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:39:59Z","timestamp":1782859199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clomipramine potentiates sorafenib efficacy in experimental hepatocellular carcinoma by targeting lysosomal sequestration and modulating the cathepsin B\/Bcl-2\/Beclin-1 axis"],"prefix":"10.1007","volume":"53","author":[{"given":"Shimaa A.","family":"Abass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Abdelrafea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramadan A.","family":"Eldomany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha A.","family":"Elsisy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherin","family":"Zakaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"2","key":"12152_CR1","doi-asserted-by":"publisher","first-page":"102446","DOI":"10.1016\/j.jceh.2024.102446","volume":"15","author":"SP Singh","year":"2025","unstructured":"Singh SP, Madke T, Chand P (2025) Global epidemiology of hepatocellular carcinoma. J Clin Experimental Hepatol 15(2):102446","journal-title":"J Clin Experimental Hepatol"},{"issue":"10","key":"12152_CR2","doi-asserted-by":"publisher","first-page":"8774","DOI":"10.3390\/curroncol30100633","volume":"30","author":"M Cerreto","year":"2023","unstructured":"Cerreto M, Cardone F, Cerrito L et al (2023) The new era of systemic treatment for hepatocellular carcinoma: from the first line to the optimal sequence. Curr Oncol 30(10):8774\u20138792","journal-title":"Curr Oncol"},{"key":"12152_CR3","doi-asserted-by":"crossref","unstructured":"Kumar K, Saraswat VA (2025) Evolving landscape of Systemic Therapy for Hepatocellular Carcinoma in 2025. J Clin Experimental Hepatol 15(5) : 102547","DOI":"10.1016\/j.jceh.2025.102547"},{"issue":"3","key":"12152_CR4","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3390\/cancers16030666","volume":"16","author":"E Kinsey","year":"2024","unstructured":"Kinsey E, Lee HM (2024) Management of hepatocellular carcinoma in 2024: the multidisciplinary paradigm in an evolving treatment landscape. Cancers 16(3):666","journal-title":"Cancers"},{"issue":"8","key":"12152_CR5","doi-asserted-by":"publisher","first-page":"102434","DOI":"10.1016\/j.clinre.2024.102434","volume":"48","author":"Y Liang","year":"2024","unstructured":"Liang Y (2024) Mechanisms of sorafenib resistance in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 48(8):102434","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"1","key":"12152_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12575-025-00281-6","volume":"27","author":"Y Zou","year":"2025","unstructured":"Zou Y, Wan X, Zhou Q et al (2025) Mechanisms of drug resistance in hepatocellular carcinoma. Biol Procedures Online 27(1):19","journal-title":"Biol Procedures Online"},{"issue":"9","key":"12152_CR7","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/sj.cdd.4401950","volume":"13","author":"C Garrido","year":"2006","unstructured":"Garrido C, Galluzzi L, Brunet M et al (2006) Mechanisms of cytochrome c release from mitochondria. Cell Death Differ 13(9):1423\u20131433","journal-title":"Cell Death Differ"},{"issue":"1","key":"12152_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cddiscovery.2016.12","volume":"2","author":"M De Castro","year":"2016","unstructured":"De Castro M, Bunt G, Wouters F (2016) Cathepsin B launches an apoptotic exit effort upon cell death-associated disruption of lysosomes. Cell Death Discovery 2(1):1\u20138","journal-title":"Cell Death Discovery"},{"issue":"4","key":"12152_CR9","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.7150\/ijbs.127929","volume":"22","author":"M Stark","year":"2026","unstructured":"Stark M, Assaraf YG (2026) Targeting Lysosomes for Enhanced Anti-Cancer Therapeutics and Immune Response. Int J Biol Sci 22(4):1693\u20131716","journal-title":"Int J Biol Sci"},{"issue":"12","key":"12152_CR10","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.3390\/ijms21124392","volume":"21","author":"J Hrab\u011bta","year":"2020","unstructured":"Hrab\u011bta J, Belhajov\u00e1 M, \u0160ubrtov\u00e1 H et al (2020) Drug sequestration in lysosomes as one of the mechanisms of chemoresistance of cancer cells and the possibilities of its inhibition. Int J Mol Sci 21(12):4392","journal-title":"Int J Mol Sci"},{"issue":"3","key":"12152_CR11","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.3390\/ijms24032176","volume":"24","author":"W Trybus","year":"2023","unstructured":"Trybus W, Trybus E, Kr\u00f3l T (2023) Lysosomes as a target of anticancer therapy. Int J Mol Sci 24(3):2176","journal-title":"Int J Mol Sci"},{"issue":"6","key":"12152_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1177\/1534735415590157","volume":"14","author":"UK Hussein","year":"2015","unstructured":"Hussein UK, Mahmoud HM, Farrag AG et al (2015) Chemoprevention of diethylnitrosamine-initiated and phenobarbital-promoted hepatocarcinogenesis in rats by sulfated polysaccharides and aqueous extract of Ulva lactuca. Integr cancer Ther 14(6):525\u2013545","journal-title":"Integr cancer Ther"},{"key":"12152_CR13","doi-asserted-by":"publisher","first-page":"120369","DOI":"10.1016\/j.lfs.2022.120369","volume":"294","author":"NM Abdel-Hamid","year":"2022","unstructured":"Abdel-Hamid NM, Abass SA, Eldomany RA et al (2022) Dual regulating of mitochondrial fusion and Timp-3 by leflunomide and diallyl disulfide combination suppresses diethylnitrosamine-induced hepatocellular tumorigenesis in rats. Life Sci 294:120369","journal-title":"Life Sci"},{"issue":"36","key":"12152_CR14","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1038\/onc.2014.25","volume":"33","author":"H Nguyen","year":"2014","unstructured":"Nguyen H, Yang J, Kung H et al (2014) Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene 33(36):4521\u20134530","journal-title":"Oncogene"},{"key":"12152_CR15","doi-asserted-by":"crossref","unstructured":"Aits S, J\u00e4\u00e4ttel\u00e4 M, Nylandsted J (2015) Methods for the quantification of lysosomal membrane permeabilization: a hallmark of lysosomal cell death, in Methods in cell biology. Elsevier. pp. 261\u2013285","DOI":"10.1016\/bs.mcb.2014.10.032"},{"issue":"1","key":"12152_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.xphs.2020.10.037","volume":"110","author":"RJ Qasem","year":"2021","unstructured":"Qasem RJ, Fallon JK, Nautiyal M et al (2021) Differential detergent fractionation of membrane protein from small samples of hepatocytes and liver tissue for quantitative proteomic analysis of drug metabolizing enzymes and transporters. J Pharm Sci 110(1):87\u201396","journal-title":"J Pharm Sci"},{"issue":"1","key":"12152_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12876-015-0311-5","volume":"15","author":"T-Y Zhao","year":"2015","unstructured":"Zhao T-Y, Su L-P, Ma C-Y et al (2015) IGF-1 decreases portal vein endotoxin via regulating intestinal tight junctions and plays a role in attenuating portal hypertension of cirrhotic rats. BMC Gastroenterol 15(1):77","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"12152_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1046\/j.1365-2559.1999.00632.x","volume":"34","author":"McDonald,Pilgram","year":"1999","unstructured":"McDonald,Pilgram (1999) Nuclear expression of p53, p21 and cyclin D1 is increased in bronchioloalveolar carcinoma. Histopathology 34(5):439\u2013446","journal-title":"Histopathology"},{"issue":"6","key":"12152_CR19","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/cancers13061292","volume":"13","author":"S Hafezi","year":"2021","unstructured":"Hafezi S, Rahmani M (2021) Targeting BCL-2 in cancer: advances, challenges, and perspectives. Cancers 13(6):1292","journal-title":"Cancers"},{"issue":"6","key":"12152_CR20","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3390\/cells10061522","volume":"10","author":"S Tran","year":"2021","unstructured":"Tran S, Fairlie WD, Lee EF (2021) BECLIN1: protein structure, function and regulation. Cells 10(6):1522","journal-title":"Cells"},{"issue":"2","key":"12152_CR21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/cancers18020288","volume":"18","author":"AM Dimesa","year":"2026","unstructured":"Dimesa AM, Coban MA, Shoari A (2026) Matrix Metalloproteinases in Hepatocellular Carcinoma: Mechanistic Roles and Emerging Inhibitory Strategies for Therapeutic Intervention. Cancers 18(2):288","journal-title":"Cancers"},{"key":"12152_CR22","doi-asserted-by":"crossref","unstructured":"Mauro E, de Castro T, Zeitlhoefler M et al (2025) Hepatocellular carcinoma: Epidemiology, diagnosis and treatment. JHEP Reports: 101571","DOI":"10.1016\/j.jhepr.2025.101571"},{"issue":"5","key":"12152_CR23","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3892\/ol.2025.15272","volume":"30","author":"M Wei","year":"2025","unstructured":"Wei M, Cao Z, Dong L et al (2025) The advantages and challenges of sorafenib combination therapy: Drug resistance, toxicity and future directions. Oncol Lett 30(5):526","journal-title":"Oncol Lett"},{"issue":"4","key":"12152_CR24","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1097\/JS9.0000000000002294","volume":"111","author":"C Huang","year":"2025","unstructured":"Huang C, Li Y, Zhang F et al (2025) Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma. Int J Surg 111(4):2990\u20133005","journal-title":"Int J Surg"},{"issue":"10","key":"12152_CR25","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41419-019-1989-z","volume":"10","author":"J Gavini","year":"2019","unstructured":"Gavini J, Dommann N, Jakob MO et al (2019) Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma. Cell Death Dis 10(10):749","journal-title":"Cell Death Dis"},{"key":"12152_CR26","doi-asserted-by":"crossref","unstructured":"Ferret L, Pol JG, Sauvat A et al (2025) Lysosomal membrane permeabilization enhances the anticancer effects of POLR1 (RNA polymerase I) transcription inhibitors. Autophagy: 1\u201320","DOI":"10.1101\/2025.03.03.641132"},{"issue":"1","key":"12152_CR27","doi-asserted-by":"publisher","first-page":"4881","DOI":"10.1038\/s41598-019-40887-x","volume":"9","author":"F Cavaliere","year":"2019","unstructured":"Cavaliere F, Fornarelli A, Bertan F et al (2019) The tricyclic antidepressant clomipramine inhibits neuronal autophagic flux. Sci Rep 9(1):4881","journal-title":"Sci Rep"},{"key":"12152_CR28","doi-asserted-by":"crossref","unstructured":"Hsu C-H, Shen Y-C, Shao Y-Y et al (2014) Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. J hepatocellular carcinoma 1(2014) : 85\u201399","DOI":"10.2147\/JHC.S45040"},{"issue":"22","key":"12152_CR29","doi-asserted-by":"publisher","first-page":"7594","DOI":"10.3390\/molecules28227594","volume":"28","author":"L He","year":"2023","unstructured":"He L, Fu Y, Tian Y et al (2023) Antidepressants as autophagy modulators for cancer therapy. Molecules 28(22):7594","journal-title":"Molecules"},{"issue":"1","key":"12152_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12943-016-0503-9","volume":"15","author":"J Ruan","year":"2016","unstructured":"Ruan J, Zheng H, Rong X et al (2016) Over-expression of cathepsin B in hepatocellular carcinomas predicts poor prognosis of HCC patients. Mol Cancer 15(1):17","journal-title":"Mol Cancer"},{"issue":"4","key":"12152_CR31","doi-asserted-by":"publisher","first-page":"395","DOI":"10.18632\/oncoscience.147","volume":"2","author":"C Amantini","year":"2015","unstructured":"Amantini C, Morelli MB, Santoni M et al (2015) Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt\/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells. Oncoscience 2(4):395","journal-title":"Oncoscience"},{"issue":"4","key":"12152_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41419-023-05786-0","volume":"14","author":"Z Xie","year":"2023","unstructured":"Xie Z, Zhao M, Yan C et al (2023) Cathepsin B in programmed cell death machinery: mechanisms of execution and regulatory pathways. Cell Death Dis 14(4):255","journal-title":"Cell Death Dis"},{"issue":"1","key":"12152_CR33","doi-asserted-by":"publisher","first-page":"4972523","DOI":"10.1155\/2024\/4972523","volume":"2024","author":"AJ de Melo Silva","year":"2024","unstructured":"de Melo Silva AJ, de Melo Gama JE, de Oliveira SA (2024) The role of Bcl-2 family proteins and sorafenib resistance in hepatocellular carcinoma. Int J Cell Biology 2024(1):4972523","journal-title":"Int J Cell Biology"},{"key":"12152_CR34","doi-asserted-by":"publisher","first-page":"1669955","DOI":"10.3389\/fceld.2025.1669955","volume":"4","author":"T Yamashima","year":"2025","unstructured":"Yamashima T (2025) Lysosomal membrane-permeabilization (LMP) and-rupture (LMR) are distinct for cell death. Front Cell Death 4:1669955","journal-title":"Front Cell Death"},{"issue":"19","key":"12152_CR35","doi-asserted-by":"publisher","first-page":"16926","DOI":"10.18632\/oncotarget.4700","volume":"6","author":"L Bongiorno-Borbone","year":"2015","unstructured":"Bongiorno-Borbone L, Giacobbe A, Compagnone M et al (2015) Anti-tumoral effect of desmethylclomipramine in lung cancer stem cells. Oncotarget 6(19):16926","journal-title":"Oncotarget"},{"issue":"1","key":"12152_CR36","doi-asserted-by":"publisher","first-page":"2529196","DOI":"10.1080\/27694127.2025.2529196","volume":"4","author":"G Righes","year":"2025","unstructured":"Righes G, Semenzato L, Koutsikos K et al (2025) The role of autophagy in the pathogenesis and treatment of multiple sclerosis. Autophagy Rep 4(1):2529196","journal-title":"Autophagy Rep"},{"issue":"4","key":"12152_CR37","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/cdd.2010.191","volume":"18","author":"R Kang","year":"2011","unstructured":"Kang R, Zeh H, Lotze M et al (2011) The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ 18(4):571\u2013580","journal-title":"Cell Death Differ"},{"issue":"4","key":"12152_CR38","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/15384047.2015.1018494","volume":"16","author":"A Grimaldi","year":"2015","unstructured":"Grimaldi A, Santini D, Zappavigna S et al (2015) Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells. Cancer Biol Ther 16(4):567\u2013579","journal-title":"Cancer Biol Ther"},{"key":"12152_CR39","doi-asserted-by":"publisher","first-page":"175883592092760","DOI":"10.1177\/1758835920927602","volume":"12","author":"G Fan","year":"2020","unstructured":"Fan G, Wei X, Xu X (2020) Is the era of sorafenib over? A review of the literature. Therapeutic Adv Med Oncol 12:1758835920927602","journal-title":"Therapeutic Adv Med Oncol"},{"issue":"2","key":"12152_CR40","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1159\/000485285","volume":"44","author":"T Sun","year":"2017","unstructured":"Sun T, Liu H, Ming L (2017) Multiple roles of autophagy in the sorafenib resistance of hepatocellular carcinoma. Cell Physiol Biochem 44(2):716\u2013727","journal-title":"Cell Physiol Biochem"},{"issue":"6","key":"12152_CR41","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1093\/carcin\/bgt063","volume":"34","author":"J Li","year":"2013","unstructured":"Li J, Yang B, Zhou Q et al (2013) Autophagy promotes hepatocellular carcinoma cell invasion through activation of epithelial\u2013mesenchymal transition. Carcinogenesis 34(6):1343\u20131351","journal-title":"Carcinogenesis"},{"issue":"1","key":"12152_CR42","first-page":"43","volume":"60","author":"N Mohie Abdel-Hamid","year":"2022","unstructured":"Mohie Abdel-Hamid N, Abass SA, Eldomany R (2022) Assessment of YME1L and mitofusin2 as a possible diagnostic and\/or therapeutic target in hepatocellular carcinoma. Indian J Biochem Biophys (IJBB) 60(1):43\u201354","journal-title":"Indian J Biochem Biophys (IJBB)"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12152-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12152-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12152-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:40:11Z","timestamp":1782859211000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12152-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12152"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12152-8","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1050"}}